Low preoperative albumin-globulin score predicts favorable survival in esophageal squamous cell carcinoma.
This study retrospectively investigated the prognostic significance of the preoperative albumin-globulin score (AGS) and albumin/globulin ratio (AGR) in esophageal squamous cell carcinoma (ESCC). A cohort of 458 newly diagnosed ESCC patients who underwent radical esophagectomy in Sun Yat-sen University Cancer Center (Guangzhou, China) between January 2006 and December 2010 were selected into this study. The optimal cut-off value was identified to be 45.6 g/L, 26.9 g/L and 1.30 for albumin (ALB), globulin (GLB) and AGR in terms of survival, respectively. Patients with low ALB levels (< 45.6 g/L) and high GLB levels (≥ 26.9 g/L) were assigned an AGS of 2, those with only one of the two abnormalities were assigned an AGS of 1, and those with neither of the two abnormalities were assigned an AGS of 0. Univariate survival analysis showed that low AGS (0) was significantly associated with favorable disease free survival (DFS) [hazard ratio (HR), 0.635; 95% confidence interval (CI), 0.441-0.914; P = 0.015] and overall survival (OS) (HR, 0.578; 95% CI, 0.387-0.862; P = 0.007), and it remained an independent predictor for OS (HR, 0.630; 95% CI, 0.418-0.952; P = 0.028), but not for DFS (HR, 0.697; 95% CI, 0.479-1.061; P = 0.060) in multivariate models. High AGR (≥ 1.30) was also correlated with favorable DFS (HR, 0.626; 95% CI, 0.430-0.910; P = 0.014) and OS (HR, 0.622; 95% CI, 0.422-0.916; P = 0.016) in univariate analysis, but it failed to be an independent prognostic indicator for DFS (HR, 0.730; 95% CI, 0.494-1.078; P = 0.114) or OS (HR, 0.759; 95% CI, 0.507-1.137; P = 0.181) by multivariate analysis. Low preoperative AGS could serve as a valuable and convenient biochemical marker to predict favorable long-term survival in ESCC patients.
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Fei
F
Zhang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Peng
P
Sun
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Zhi-Qiang
ZQ
Wang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
De Shen
de S
Wang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Yun
Y
Wang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Dong-Sheng
DS
Zhang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Feng-Hua
FH
Wang
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Jian-Hua
JH
Fu
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Rui-Hua
RH
Xu
Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, People's Republic of China.|State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, People's Republic of China.|Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
Yu-Hong
YH
Li
D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000601:surgery / Q000628:therapy; D059248:Chemoradiotherapy; D018572:Disease-Free Survival; D004938:Esophageal Neoplasms / Q000378:metabolism* / Q000601:surgery / Q000628:therapy; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D057234:Preoperative Period; D011379:Prognosis; D012189:Retrospective Studies; D012709:Serum Albumin / Q000032:analysis*; D012712:Serum Globulins / Q000032:analysis*
D012709:Serum Albumin; D012712:Serum Globulins
albumin-globulin score; albumin/globulin ratio; esophageal squamous cell carcinoma; survival